Cochrane · systematic review · CD011823
Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Schuit Ewoud, Panagiotou Orestis A., Munafò Marcus R, et al. · Cochrane Database of Systematic Reviews · 2017 · Cochrane Library
Tobacco AddictionAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
38
current version
GRADE rated
38
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 5 · 13.2%Low 17 · 44.7%Moderate 13 · 34.2%High 3 · 7.9%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Active NRT compared with placebo ‐ rs1051730 ‐ non‐Hispanic white for smoking cessation
Population: people who smoke
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Abstinence at end of treatment Active NRT vs placebo ‐ rs1051730 ‐ non‐Hispanic white | RR 1.63 [1.14, 2.32] | 2 studies · 1391 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency |
Abstinence at end of treatment ‐ homozygous major Active NRT vs placebo ‐ rs1051730 ‐ non‐Hispanic white | RR 1.09 [0.85, 1.41] | 2 studies · 582 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Abstinence at end of treatment ‐ heterozygous Active NRT vs placebo ‐ rs1051730 ‐ non‐Hispanic white | RR 2.13 [1.52, 2.97] | 2 studies · 631 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency |
Abstinence at end of treatment ‐ homozygous minor Active NRT vs placebo ‐ rs1051730 ‐ non‐Hispanic white | RR 2.18 [1.04, 4.58] | 2 studies · 178 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Active NRT compared with placebo ‐ rs16969968 ‐ non‐Hispanic white for smoking cessation
Population: people who smoke
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
End of treatment Active NRT vs placebo ‐ rs16969968 ‐ non‐Hispanic white | RR 1.38 [0.97, 1.98] | 2 studies · 1127 participants | Moderate Downgraded: imprecision |
End of treatment ‐ homozygous major Active NRT vs placebo ‐ rs16969968 ‐ non‐Hispanic white | RR 1.01 [0.77, 1.33] | 2 studies · 449 participants | Low Downgraded: imprecision |
End of treatment ‐ heterozygous Active NRT vs placebo ‐ rs16969968 ‐ non‐Hispanic white | RR 1.85 [1.33, 2.59] | 2 studies · 550 participants | High |
End of treatment ‐ homozygous minor Active NRT vs placebo ‐ rs16969968 ‐ non‐Hispanic white | RR 1.8 [0.45, 7.23] | 2 studies · 128 participants | Low Downgraded: imprecision, inconsistency |
Active NRT compared with placebo ‐ rs16969968 ‐ non‐Hispanic black or African American for smoking cessation
Population: people who smoke
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Abstinence at 6 months Active NRT vs placebo ‐ rs16969968 ‐ non‐Hispanic black or African American | RR 1.11 [0.55, 2.26] | 2 studies · 709 participants | Moderate Downgraded: inconsistency |
Abstinence at 6 months ‐ homozygous major Active NRT vs placebo ‐ rs16969968 ‐ non‐Hispanic black or African American | RR 1.47 [1.07, 2.03] | 2 studies · 637 participants | High |
Abstinence at 6 months ‐ heterozygous or homozygous minor Active NRT vs placebo ‐ rs16969968 ‐ non‐Hispanic black or African American | RR 0.43 [0.15, 1.26] | 2 studies · 72 participants | Low Downgraded: imprecision, inconsistency |
Abstinence at end of treatment Active NRT vs placebo ‐ rs16969968 ‐ non‐Hispanic black or African American | RR 1.03 [0.36, 2.94] | 2 studies · 709 participants | Moderate Downgraded: inconsistency |
Abstinence at end of treatment ‐ homozygous major Active NRT vs placebo ‐ rs16969968 ‐ non‐Hispanic black or African American | RR 1.57 [1.15, 2.15] | 2 studies · 637 participants | High |
Abstinence at end of treatment ‐ heterozygous or homozygous minor Active NRT vs placebo ‐ rs16969968 ‐ non‐Hispanic black or African American | RR 0.29 [0.1, 0.86] | 2 studies · 72 participants | Moderate Downgraded: imprecision, inconsistency |
Active NRT compared with placebo ‐ rs 588765 ‐ non‐Hispanic white for smoking cessation
Population: people who smoke
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
End of treatment Active NRT vs placebo ‐ rs 588765 ‐ non‐Hispanic white | RR 1.33 [1.04, 1.71] | 2 studies · 923 participants | Moderate Downgraded: imprecision |
End of treatment ‐ homozygous major Active NRT vs placebo ‐ rs 588765 ‐ non‐Hispanic white | RR 1.39 [0.89, 2.16] | 2 studies · 296 participants | Low Downgraded: imprecision |
End of treatment ‐ heterozygous Active NRT vs placebo ‐ rs 588765 ‐ non‐Hispanic white | RR 1.27 [0.89, 1.79] | 2 studies · 469 participants | Low Downgraded: imprecision |
End of treatment ‐ homozygous minor Active NRT vs placebo ‐ rs 588765 ‐ non‐Hispanic white | RR 1.5 [0.74, 3.06] | 2 studies · 158 participants | Low Downgraded: imprecision |
Active NRT compared with placebo ‐ rs2036527 ‐ non‐Hispanic black or African American for smoking cessation
Population: people who smoke
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
6‐Month abstinence Active NRT vs placebo ‐ rs2036527 ‐ non‐Hispanic black or African American | RR 1.18 [0.75, 1.87] | 2 studies · 708 participants | Low Downgraded: imprecision |
6‐Month abstinence ‐ homozygous major Active NRT vs placebo ‐ rs2036527 ‐ non‐Hispanic black or African American | RR 1.95 [0.46, 8.26] | 2 studies · 425 participants | Very low Downgraded: imprecision |
6‐Month abstinence ‐ heterozygous or homozygous minor Active NRT vs placebo ‐ rs2036527 ‐ non‐Hispanic black or African American | RR 0.9 [0.4, 2.03] | 2 studies · 283 participants | Moderate Downgraded: imprecision |
End of treatment Active NRT vs placebo ‐ rs2036527 ‐ non‐Hispanic black or African American | RR 1.22 [0.77, 1.93] | 2 studies · 708 participants | Low Downgraded: imprecision |
End of treatment ‐ homozygous major Active NRT vs placebo ‐ rs2036527 ‐ non‐Hispanic black or African American | RR 2.39 [0.43, 13.35] | 2 studies · 425 participants | Low Downgraded: imprecision |
End of treatment ‐ heterozygous or homozygous minor Active NRT vs placebo ‐ rs2036527 ‐ non‐Hispanic black or African American | RR 0.89 [0.55, 1.46] | 2 studies · 283 participants | Moderate Downgraded: imprecision |
Active NRT compared with placebo ‐ DRD4 (exon 3 48 bp) ‐ non‐Hispanic white for smoking cessation
Population: people who smoke
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
6‐Month abstinence Active NRT vs placebo ‐ DRD4 (exon 3 48 bp) ‐ non‐Hispanic white | RR 1.44 [1.08, 1.92] | 2 studies · 900 participants | Low Downgraded: risk of bias |
6‐month abstinence ‐ homozygous major Active NRT vs placebo ‐ DRD4 (exon 3 48 bp) ‐ non‐Hispanic white | RR 1.34 [0.93, 1.93] | 2 studies · 566 participants | Very low Downgraded: risk of bias |
6‐Month abstinence ‐ heterozygous Active NRT vs placebo ‐ DRD4 (exon 3 48 bp) ‐ non‐Hispanic white | RR 1.76 [1, 3.1] | 2 studies · 290 participants | Low Downgraded: risk of bias |
6‐Month abstinence ‐ homozygous minor Active NRT vs placebo ‐ DRD4 (exon 3 48 bp) ‐ non‐Hispanic white | RR 1.28 [0.4, 4.11] | 2 studies · 44 participants | Very low Downgraded: risk of bias |
End of treatment Active NRT vs placebo ‐ DRD4 (exon 3 48 bp) ‐ non‐Hispanic white | RR 1.2 [0.88, 1.63] | 2 studies · 900 participants | Low Downgraded: risk of bias |
End of treatment ‐ homozygous major Active NRT vs placebo ‐ DRD4 (exon 3 48 bp) ‐ non‐Hispanic white | RR 1.22 [0.59, 2.51] | 2 studies · 566 participants | Very low Downgraded: risk of bias |
End of treatment ‐ heterozygous Active NRT vs placebo ‐ DRD4 (exon 3 48 bp) ‐ non‐Hispanic white | RR 1.4 [0.57, 3.39] | 2 studies · 290 participants | Very low Downgraded: risk of bias |
End of treatment ‐ homozygous minor Active NRT vs placebo ‐ DRD4 (exon 3 48 bp) ‐ non‐Hispanic white | RR 1.02 [0.65, 1.58] | 2 studies · 44 participants | Low Downgraded: risk of bias |
Active NRT compared with placebo ‐ NMR ‐ non‐Hispanic black and white for smoking cessation
Population: people who smoke
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
6‐Month abstinence Active NRT vs placebo ‐ NMR ‐ non‐Hispanic black and white | RR 1.51 [1.08, 2.1] | 2 studies · 1417 participants | Moderate Downgraded: risk of bias |
6‐Month abstinence ‐ slow NMR Active NRT vs placebo ‐ NMR ‐ non‐Hispanic black and white | RR 1.82 [1.12, 2.94] | 2 studies · 628 participants | Moderate Downgraded: risk of bias |
6‐Month abstinence ‐ normal NMR Active NRT vs placebo ‐ NMR ‐ non‐Hispanic black and white | RR 1.21 [0.78, 1.87] | 2 studies · 789 participants | Low Downgraded: risk of bias, imprecision |
End of treatment Active NRT vs placebo ‐ NMR ‐ non‐Hispanic black and white | RR 1.51 [1.19, 1.9] | 2 studies · 1417 participants | Moderate Downgraded: risk of bias |
End of treatment ‐ slow NMR Active NRT vs placebo ‐ NMR ‐ non‐Hispanic black and white | RR 1.61 [1.18, 2.2] | 2 studies · 847 participants | Moderate Downgraded: risk of bias |
End of treatment ‐ normal NMR Active NRT vs placebo ‐ NMR ‐ non‐Hispanic black and white | RR 1.49 [0.85, 2.6] | 2 studies · 570 participants | Low Downgraded: risk of bias |